Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and ... "I still put a lot of patients on adalimumab [Humira] because I think the TNF inhibitors ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Symptoms can include itching, pain, or swelling. Humira can also cause new or worsen psoriasis, a condition Humira is approved to treat. Psoriasis is a skin condition that causes symptoms such as ...

Humira is already off-patent and losing ground to rivals in Europe, although AbbVie’s legal defences have so far held fast in the US, preventing competition from biosimilars until 2023.

Moderate to severe scalp psoriasis severely affects quality of life, with high DLQI scores and significant symptoms like itch, pain, and flaking. Deucravacitinib, a tyrosine kinase 2 inhibitor ...

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become ... but secondary endpoints included Psoriasis Area and Severity Index (PASI) 90, ACR 50, and physical function scores.